{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:28:30Z","timestamp":1773422910017,"version":"3.50.1"},"reference-count":5,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jaad.2024.06.099","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T06:41:52Z","timestamp":1722926512000},"page":"e167-e168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comments on the risk of cutaneous T cell lymphoma among patients with atopic dermatitis receiving dupilumab"],"prefix":"10.1016","volume":"91","author":[{"given":"Tai-Li","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Hsiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2024.06.099_bib1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jaad.2024.03.039","article-title":"Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study","volume":"91","author":"Hasan","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.06.099_bib2","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jaci.2022.02.015","article-title":"T cells in the skin: lymphoma and inflammatory skin disease","volume":"149","author":"Roediger","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2024.06.099_bib3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00403-022-02360-0","article-title":"Lifestyle, demographic and Skindex measures associated with cutaneous T-cell lymphoma: a single institution cohort study","volume":"315","author":"Nguyen","year":"2023","journal-title":"Arch Dermatol Res"},{"issue":"Pt 3","key":"10.1016\/j.jaad.2024.06.099_bib4","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.semcancer.2021.12.003","article-title":"Molecular pathogenesis of Cutaneous T cell Lymphoma: role of chemokines, cytokines, and dysregulated signaling pathways","volume":"86","author":"Patil","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"10.1016\/j.jaad.2024.06.099_bib5","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc'h","year":"2020","journal-title":"Allergy"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224025738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224025738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T06:46:12Z","timestamp":1732085172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962224025738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0190962224025738"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2024.06.099","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comments on the risk of cutaneous T cell lymphoma among patients with atopic dermatitis receiving dupilumab","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2024.06.099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}